Multiple lines of evidence are known to implicate inflammation to schizophrenia. This chapter summarizes the evidence for changes in inflammatory biomarkers and the role of inflammation in schizophrenia. Current evidence indicates changes in immune biomarkers at all stages of schizophrenia, from clinical high-risk for psychosis individuals to chronic patients. Antipsychotic therapy also affects immune biomarkers. Inflammatory parameters are associated with positive and negative symptoms, cognitive impairment, and structural brain abnormalities. Mendelian randomization studies have provided evidence of causal links between inflammation and schizophrenia. Neuroinflammation contributes to neurotransmitter abnormalities, oxidative stress, and functional dysconnectivity in the brain. The involvement of chronic low-grade inflammation in the pathogenesis of schizophrenia opens new possibilities for personalized anti-inflammatory therapy in schizophrenia.